Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

在2024年斩获1500万美元种子轮融资的基础上，Bambusa Therapeutics日前再获9000万美元A轮资金加持，持续深化其在免疫-炎症领域双特异性抗体疗法的创新布局。 本轮本轮融资由RA Capital ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

February 20, 2025, Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...